To investigate serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients, we examined the concentrations of serum tumor markers in 232 ovarian cancer patients and 219 controls with benign gynecologic diseases and screened the entire coding exons and exon‐intron boundaries of BRCA1/2 in ovarian cancer patients. This evidence concerns the gene BRCA1 and ovarian carcinoma.